Regulatory ambivalence and the limitations of pharmaceutical policy in Spain

dc.contributor.author Costa, Joanca
dc.contributor.author Puig i Junoy, Jaumeca
dc.contributor.other Universitat Pompeu Fabra. Departament d'Economia i Empresaca
dc.date.issued 2004-06-01ca
dc.date.modified 2016-09-29T02:50:24Zca
dc.format.mimetype application/pdfca
dc.identifier https://econ-papers.upf.edu/ca/paper.php?id=762ca
dc.identifier.citation Journal of Pharmaceutical Finance, Economics & POlicy 2005;13(4): 33-49ca
dc.identifier.uri http://hdl.handle.net/10230/296ca
dc.language.iso engca
dc.relation.ispartofseries Economics and Business Working Papers Series; 762ca
dc.rights L'accés als continguts d'aquest document queda condicionat a l'acceptació de les condicions d'ús establertes per la següent llicència Creative Commonsca
dc.rights.accessRights info:eu-repo/semantics/openAccessca
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/3.0/es/ca
dc.subject.keyword Labour, Public, Development and Health Economicsca
dc.subject.keyword spainca
dc.subject.keyword generic penetrationca
dc.subject.keyword reference pricingca
dc.subject.keyword negative listsca
dc.subject.keyword pharmaceutical regulationca
dc.title Regulatory ambivalence and the limitations of pharmaceutical policy in Spainca
dc.type info:eu-repo/semantics/workingPaperca

Col·leccions